Revelation Biosciences (REVB)
(Delayed Data from NSDQ)
$1.84 USD
-0.22 (-10.68%)
Updated May 13, 2024 03:59 PM ET
After-Market: $1.84 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
REVB 1.84 -0.22(-10.68%)
Will REVB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for REVB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for REVB
Bears are Losing Control Over Revelation Biosciences, Inc. (REVB), Here's Why It's a 'Buy' Now
REVB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for REVB
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024
Revelation Biosciences GAAP EPS of -$2.46
Revelation Biosciences reports Q1 EPS ($2.46), consensus ($5.38)
Revolution Beauty Discloses Total Voting Rights
Revolution Beauty Group’s Stake Shift to UBS